Trials / Unknown
UnknownNCT02822326
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
CD19-CAR-T2 Cells for Relapse/Refractory CD19 Positive Acute Leukemia-a Phase I Trial
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of chimeric antigen receptor 19 (CD19-CAR-T2 Cells) infusions in patients with chemotherapy resistant or refractory CD19+ acute Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19-CAR-T2 Cells |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2016-07-04
- Last updated
- 2017-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02822326. Inclusion in this directory is not an endorsement.